in the discussion, the new Zamboni paper says:
Another influential factor of the favorable outcome of our RR group could be the continuing immunomodulating treatment, which is well known to be capable of significantly reducing relapse rates as well as MRI-detectable Gad+ lesions. It does, however, appear that endovascular treatment of concomitant CCSVI may have an additional benefit on lesions activity.
I think that's a really clever move and should be considered by everyone who promotes CCSVI and it's treatment. "Selling" it as ADDITIONAL rather than alternative treatment is something even neuros and drug companies can feel comfortable with. (If a trial is set up with only MSers getting CCSVI treatment WHILE taking CRABs, it could even make sense for drug companies to fund it - nevertheless showing the effects of the vascular treatment alone to those who want to read it like that). It could lead to a future where one can choose to have drugs, CCSVI treatment or both (or still nothing of course), all paid by insurance. Which would be just fine for everybody here, I guess.
Although I would be rolling in money if I could bet on which of the four ways people in this forum choose.